S

Synthaverse SA
WSE:SVE

Watchlist Manager
Synthaverse SA
WSE:SVE
Watchlist
Price: 4.14 PLN -2.47% Market Closed
Market Cap: 293m PLN
Have any thoughts about
Synthaverse SA?
Write Note

Synthaverse SA
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Synthaverse SA
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
S
Synthaverse SA
WSE:SVE
Capital Expenditures
-zł108m
CAGR 3-Years
-181%
CAGR 5-Years
-123%
CAGR 10-Years
-45%
M
Mabion SA
WSE:MAB
Capital Expenditures
-zł31.4m
CAGR 3-Years
-20%
CAGR 5-Years
-23%
CAGR 10-Years
0%
R
Read Gene SA
WSE:RDG
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genomed SA
WSE:GEN
Capital Expenditures
-zł203.9k
CAGR 3-Years
41%
CAGR 5-Years
32%
CAGR 10-Years
N/A
B
Bioton SA
WSE:BIO
Capital Expenditures
-zł24.6m
CAGR 3-Years
-55%
CAGR 5-Years
15%
CAGR 10-Years
N/A
U
Urteste SA
WSE:URT
Capital Expenditures
-zł1.7m
CAGR 3-Years
-246%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Synthaverse SA
Glance View

Market Cap
292m PLN
Industry
Biotechnology

Biomed Lublin Wytwornia Surowic i Szczepionek SA engages in the manufacture of pharmaceutical products. The company is headquartered in Lublin, Woj. Lubelskie and currently employs 234 full-time employees. The company went IPO on 2011-07-29. The firm focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The firm offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The firm supplies its products to 50 countries around the world.

SVE Intrinsic Value
6.96 PLN
Undervaluation 40%
Intrinsic Value
Price
S

See Also

What is Synthaverse SA's Capital Expenditures?
Capital Expenditures
-108m PLN

Based on the financial report for Jun 30, 2024, Synthaverse SA's Capital Expenditures amounts to -108m PLN.

What is Synthaverse SA's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-45%

Over the last year, the Capital Expenditures growth was -64%. The average annual Capital Expenditures growth rates for Synthaverse SA have been -181% over the past three years , -123% over the past five years , and -45% over the past ten years .

Back to Top